Role of levosimendan in intensive care treatment of myocardial insufficiency;Rolle von levosimendan in der intensivmedizinischen behandlung des myokardialen pumpversagens

Anaesthesist

Volumn 56, Issue 1, 2007, Pages 30-43

  Rehberg, S ^b   Ertmer, C ^b   Van Aken, H ^b   Lange, M ^b   Broking K ^b   Morelli, A ^a   Westphal, M ^b  

^a Klinik für Anästhesie und Intensivmedizin   (Italy)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Calcium sensitizer; Heart failure; Inotropic agents; Intensive care medicine; Myocardial ischemia

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGITALIS; DIURETIC AGENT; DOBUTAMINE; FUROSEMIDE; GLYCERYL TRINITRATE; LEVOSIMENDAN; MILRINONE; NESIRITIDE; NITRATE; PLACEBO;

CLINICAL TRIAL; DRUG MECHANISM; DRUG METABOLISM; HEART FAILURE; HEMODYNAMICS; HUMAN; INTENSIVE CARE; MORTALITY; REVIEW; RISK ASSESSMENT; SURVIVAL;

CALCIUM; CARDIAC OUTPUT, LOW; CARDIOTONIC AGENTS; HUMANS; HYDRAZONES; INTENSIVE CARE; MYOCARDIAL ISCHEMIA; POSTOPERATIVE CARE; PYRIDAZINES;

EID: 33846603719     PISSN: 00032417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00101-006-1108-2     Document Type: Review

References (107)

1. Adamopoulos S, Parissis JT, Iliodromitis EK et al. (2006) Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol 98(1): 102-106. Epub 2006 May 6
2. Anand IS, Fisher LD, Chiang YT et al. for the Val-HeFT Investigators (2003) Changes in brain natriuretic peptide norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107: 1278-1283
3. Antila S, Eha J, Heinpalu M et al. (1996) Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril. Eur J Clin Pharmacol 49(6): 451-458
4. Barisin S, Husedzinovic I, Sonicki Z et al. (2004) Levosimendan in off-pump coronary artery bypass: a four-times masked controlled study. J Cardiovasc Pharmacol 44: 703-708
5. Bowman P, Haikala H, Paul RJ (1999) Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization. J Pharmacol Exp Ther 288(1): 316-325
6. Braun JP, Schneider M, Kastrup M, Liu J (2004) Treatment of acute heart failure in an infant after cardiac surgery using levosimendan. Eur J Cardiothorac Surg 26: 228-230
7. Cammarata G, Weil MH, Sun S et al. (2006) Levosimendan improves cardiopulmonary resuscitation and survival by K(ATP) channel activation. J Am Coll Cardiol 47: 1082-1090
8. Cuffe MS, Califf RM, Adams KF Jr et al. (2002) Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 287: 1541-1547
9. Delle Karth G, Buberl A, Geppert A et al. (2003) Hemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholamines. Acta Anaesthesiol Scand 47(10): 1251-1256
10. Digitalis Investigation Group (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336: 525-533
11. Edes I, Kiss E, Kitada Y et al. (1995) Effects of levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res 77(1): 107-113
12. Endoh M (2001) Mechanism of action of Ca2+ sensitizers - update 2001. Cardiovasc Drugs Ther 15(5): 397-403
13. Fischbach PS, White A, Barrett TD, Lucchesi BR (2004) Risk of ventricular proarrhythmia with selective opening of the myocardial sarcolemmal versus mitochondrial ATP-gated potassium channel. J Pharmacol Exp Ther 309: 554-559
14. Follath F, Cleland JG, Just H et al.; Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) (2002) Study efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 360(9328): 196-202
15. Gegenhuber A, Mueller T, Firlinger F et al. (2004) Time course of B-type natriuretic peptide (BNP) and N-terminal proBNP changes in patients with decompensated heart failure. Clin Chem 50: 454-456
16. Gross GJ, Fryer RM (1999) Sarcolemmal versus mitochondrial ATP-sensitive K+ channels and myocardial preconditioning. Circ Res 84: 973-979
17. Gross GJ, Peart JN (2003) KATP channels and myocardial preconditioning. An update. Am J Physiol Heart Circ Physiol 285: H921-930
18. Haikala H, Kaivola J, Nissinen E et al. (1995) Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 27(9): 1859-1866
19. Haikala H, Nissinen E, Etemadzadeh E et al. (1995) Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol 25(5): 794-801
20. Hasenfuss G, Holubarsch C, Heiss HW et al. (1989) Myocardial energetics in patients with dilated cardiomyopathy: influence of nitroprusside and enoximone. Circulation 80: 51-64
21. Hasenfuss G, Pieske B, Castell M et al. (1998) Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation 98(20): 2141-2147
22. Hillege HL, Girbes AR, Kam PJ de et al. (2000) Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 102: 203-210
23. Hosenpud JD, for the Oral Levosimendan Study Group (1999) Levosimendan, a novel myofilament calcium sensitizer, allows weaning of parenteral inotropic therapy in patients with severe congestive heart failure. Am J Cardiol 83: 9(I)-11(I)
24. Jamali IN, Kersten JR, Pagel PS et al. (1997) Intracoronary levosimendan enhances contractile function of stunned myocardium. Anesth Analg 85(1): 23-29
25. Janssen PM, Datz N, Zeitz O, Hasenfuss G (2000) Levosimendan improves diastolic and systolic function in failing human myocardium. Eur J Pharmacol 404: 191-199
26. Jonsson EN, Antila S, McFadyen L et al. (2003) Population pharmacokinetics of levosimendan in patients with congestive heart failure. Br J Clin Pharmacol 55(6): 544-551
27. Kersten JR, Montgomery MW, Pagel PS, Warltier DC (2000) Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of KATP channels. Anesth Analg 90: 5-11
28. Kivikko M, Antila S, Eha J et al. (2002) Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. J Clin Pharmacol 42: 43-51
29. Kivikko M, Lehtonen L, Colucci WS (2003) Sustained hemodynamic effects of intravenous levosimendan. Circulation 107: 81-86
30. Kopustinskiene DM, Pollesello P, Saris NE (2004) Potassium-specific effects of levosimendan on heart mitochondria. Biochem Pharmacol 68: 807-812
31. Kristof E, Szigeti G, Papp Z et al. (1998) Cardiac responses to calcium sensitizers and isoproterenol in intact guinea pig hearts: effects on cyclic AMP levels, protein phosphorylation, myoplasmic calcium concentration, and left ventricular function. Ann N Y Acad Sci 853: 316-319
32. Kristof E, Szigeti G, Papp Z et al. (1999) The effects of levosimendan on the left ventricular function and protein phosphorylation in post-ischemic guinea pig hearts. Basic Res Cardiol 94: 223-230
33. Kumar S (2003) Dobutamine kills good hearts! Levosimendan may not. Internet J Cardiol 2(1).http://www.ispub.com/ostia/index.php?xmlFilePath= journals/ijc/vol2n1/dobutamine. xml. Cited 27 Oct 2006
34. Labriola C, Siro Brigiani M, Carrata F et al. (2004) Hemodynamic effects of levosimendan in patients with low-output heart failure after cardiac surgery. Int J Clin Pharmacol Ther 42: 204-211
35. Leather HA, Eycken K ver, Segers P et al. (2003) Effects of levosimendan on right ventricular function and ventriculovascular coupling in open chest pigs. Crit Care Med 31: 2339-2343
36. Lehmann A, Lang J, Boldt J et al. (2004) Levosimendan in patients with cardiogenic shock undergoing surgical revascularization: a case series. Med Sci Monit 10: MT89-93
37. Lehtonen L, Sundberg S (2002) The contractility enhancing effect of the calcium sensitiser levosimendan is not attenuated by carvedilol in healthy subjects. Eur J Clin Pharmacol 58: 449-452
38. Lilleberg J, Nieminen MS, Akkila J et al. (1998) Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J 19: 660-668
39. Lilleberg J, Ylonen V, Lehtonen L, Toivonen L (2004) The calcium sensitizer levosimendan and cardiac arrhythmias: an analysis of the safety database of heart failure treatment studies. Scand Cardiovasc J 38: 80-84
40. Luca L de, Proietti P, Celotto A et al. (2005) Levosimendan improves hemodynamics and coronary flow reserve after percutaneous coronary intervention in patients with acute myocardial infarction and left ventricular dysfunction. Am Heart J 150(3): 563-568
41. Luca L de, Sardella G, Proietti P et al. (2006) Effects of levosimendan on left ventricular diastolic function after primary angioplasty for acute anterior myocardial infarction: a Doppler echocardiographic study. J Am Soc Echocardiogr 19(2): 172-177
42. Maytin M, Colucci WS (2005) Cardioprotection: a new paradigm in the management of acute heart failure syndromes. Am J Cardiol 96(6A): 26G-31G
43. McGough MF, Pagel PS, Lowe D et al. (1996) Levosimendan potentiates the inotropic actions of dopamine in conscious dogs. J Cardiovasc Pharmacol 28: 36-47
44. McGough MF, Pagel PS, Lowe D et al. (1997) Effects of levosimendan on left ventricular function: correlation with plasma concentrations in conscious dogs. J Cardiothorac Vasc Anesth 11: 49-53
45. Mebazaa A (2005) The survival of patients with acute heart failure in need of intravenous inotropic support (SURVIVE) trial. Late-breaking clinical trials. American Heart Association, Annual Scientific Session, Dallas TX
46. Mebazaa A, Cohen-Solal A, Kleber F (2004) Study design of a mortality trial with intravenous levosimendan (the SURVIVE study) in patients with acutely decompensated heart failure. Crit Care 8: 87
47. Michaels AD, McKeown B, Kostal M et al. (2005) Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake. Circulation 111: 1504-1509
48. Moiseyev VS, Poder P, Andrejevs N et al. (2002) Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction: a randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 23: 1422-1432
49. Morelli A, Castro S de, Teboul JL et al. (2005) Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med 31: 638-644
50. Morelli A, Teboul JL, Maggiore SM et al. (2006) Effects of levosimendan on right ventricular afterload in patients with acute respiratory distress syndrome: A pilot study. Crit Care Med 34(9): 2287-2293
51. Nakae Y, Fujita S, Namki A (2001) Isoproterenol enhances myofilament Ca(2+) sensitivity during hypothermia in isolated guinea pig beating hearts. Anesth Analg 93: 846-852
52. Nanas JN, Papazoglou PP, Terrovitis JV et al. (2004) Hemodynamic effects of levosimendan added to dobutamine in patients with decompensated advanced heart failure refractory to dobutamine alone. Am J Cardiol 94: 1329-1332
53. Nanas JN, Papazoglou P, Tsagalou EP et al. (2005) Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine alone. Am J Cardiol 95: 768-771
54. Nicklas JM, Monsur JC, Bleske BE (1999) Effects of intravenous levosimendan on plasma neurohormone levels in patients with heart failure: relation to hemodynamic response. Am J Cardiol 83: 12(I)-15(I)
55. Nieminen MS, Akkila J, Hasenfuss G et al. (2000) Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 36: 1903-1912
56. Nieminen MS, Bohm M, Cowie MR et al. (2005) Executive summary of the guidelines on the diagnosis and treatment of acute heart failure. The Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 26: 384-416
57. Nijhawan N, Nicolosi AC, Montgomery MW et al. (1999) Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial. J Cardiovasc Pharmacol 34: 219-228
58. Noto A, Giacomini M, Palandi A et al. (2005) Levosimendan in septic cardiac failure. Intensive Care Med 31: 164-165
59. Oldner A, Konrad D, Weitzberg E et al. (2001) Effects of levosimendan, a novel inotropic calcium-sensitizing drug, in experimental septic shock. Crit Care Med 29: 2185-2193
60. Packer M (1993) The search for the ideal positive inotropic agent. N Engl J Med 329: 201-202
61. Packer M (2005) The randomized multicenter evaluation of intravenous levosimendan efficacy (REVIVE-2) trial. Late-breaking clinical trials. American Heart Association, Annual Scientific Session, Dallas TX
62. Packer M, Colucci WS, Fisher L (2003) Development of a comprehensive new endpoint for the evaluation of new treatments for acute decompensated heart failure: results with levosimendan in the REVIVE-1 study. J Cardiac Failure 9: 61
63. Pagel PS, Hettrick DA, Warltier DC (1996) Influence of levosimendan, pimobendan, and milrinone on the regional distribution of cardiac output in anaesthetized dogs. Br J Pharmacol 119: 609-615
64. Pagel PS, Hettrick DA, Warltier DC (1996) Comparison of the effects of levosimendan, pimobendan, and milrinone on canine left ventricular-arterial coupling and mechanical efficiency. Basic Res Cardiol 91: 296-307
65. Pagel PS, McGough MF, Hettrick DA et al. (1997) Levosimendan enhances left ventricular systolic and diastolic function in conscious dogs with pacing-induced cardiomyopathy. J Cardiovasc Pharmacol 29: 563-573
66. Papp Z, Csapo K, Pollesello P et al. (2005) Pharmacological mechanisms contributing to the clinical efficacy of levosimendan. Cardiovasc Drug Rev 23(1): 71-98
67. Parissis J, Panou F, Farmakis D et al. (2005) Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. Am J Cardiol 96: 423-426
68. Parissis JT, Adamopoulos S, Antoniades C et al. (2004) Effects of levosimendan on circulating proinflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol 93(10): 1309-1312
69. Perez NG, Marban E, Cingolani HE (1999) Preservation of myofilament calcium responsiveness underlies protection against myocardial stunning by ischemic preconditioning. Cardiovasc Res 42: 636-643
70. Pieske B (2002) Levosimendan in regional myocardial ischemia. Cardiovasc Drugs Ther 16: 379-381
71. Ploechl W, Rajek A (2004) The use of the novel calcium sensitizer levosimendan in critically ill patients. Anaesth Intensive Care 32: 471-475
72. Poder P, Eha J, Antila S et al. (2003) Pharmacodynamic interactions of levosimendan and felodipine in patients with coronary heart disease. Cardiovasc Drugs Ther 17: 451-458
73. Poder P, Eha J, Sundberg S et al. (2004) Pharmacodynamics and pharmacokinetics of oral levosimendan and its metabolites in patients with severe congestive heart failure: a dosing interval study. J Clin Pharmacol 44: 1143-1150
74. Remme WJ, Swedberg K (2001) Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 22: 1527-1560
75. Rivers E, Nguyen B, Havstad S et al.; Early Goal-Directed Therapy Collaborative Group (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345(19): 1368-1377
76. Rokyta R Jr, Pechman V (2006) The effects of Levosimendan on global haemodynamics in patients with cardiogenic shock. Neuro Endocrinol Lett 27(1-2): 121-127 [Epub ahead of print]
77. Rump AF, Acar D, Rosen R, Klaus W (1994) Functional and antiischaemic effects of the phosphodiesterase inhibitor levosimendan in isolated rabbit hearts. Pharmacol Toxicol 74: 244-248
78. Russ MA, Prondzeisky R, Reith S (2005) Profound hemodynamic improvement following levosimendan in patients with acute myocardial infarction and severe cardiogenic shock. Circulation 112: II-423
79. Sandell EP, Hayha M, Antila S et al. (1995) Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure. J Cardiovasc Pharmacol 26 [Suppl 1]: S57-62
80. Schwarte LA, Picker O, Bornstein SR et al. (2005) Levosimendan is superior to milrinone and dobutamine in selectively increasing microvascular gastric mucosal oxygenation in dogs. Crit Care Med 33: 135-142
81. Scoote M, Williams AJ (2004) Myocardial calcium signalling and arrhythmia pathogenesis. Biochem Biophys Res Commun 322: 1286-1309
82. Shammas FV, Dickstein K (1988) Clinical pharmacokinetics in heart failure. Clin Pharmacokinet 15: 94-113
83. Singh BN, Lilleberg J, Sandell E-P et al. (1999) Effects of levosimendan on cardiac arrhythmia: electrophysiologic and ambulatory electrocardiographic findings in phase II and phase III clinical studies in cardiac failure. Am J Cardiol 83: 16-20
84. Slawsky MT, Colucci WS, Gottlieb SS et al. (2000) Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 102: 2222-2227
85. Sonntag S, Sundberg S, Lehtonen LA, Kleber FX (2004) The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J Am Coll Cardiol 43: 2177-2182
86. Sorsa T, Pollesello P, Solaro RJ (2004) The contractile apparatus as a target for drugs against heart failure: interaction of levosimendan, a calcium sensitiser, with cardiac troponin c. Mol Cell Biochem 266(1-2): 87-107
87. Sundberg S, Lehtonen L (2000) Haemodynamic interactions between the novel calcium sensitiser levosimendan and isosorbide-5-mononitrate in healthy subjects. Eur J Clin Pharmacol 55: 793-799
88. Szilagyi S, Pollesello P, Levijoki J et al. (2005) Two inotropes with different mechanisms of action: contractile, PDE-inhibitory and direct myofibrillar effects of levosimendan and enoximone. J Cardiovasc Pharmacol 46(3): 369-376
89. Tachibana H, Cheng HJ, Ukai T et al. (2005) Levosimendan improves LV systolic and diastolic performance at rest and during exercise after heart failure. Am J Physiol Heart Circ Physiol 288: H914-922
90. Tassani P, Schad H, Heimisch W et al. (2002) Effect of the calcium sensitizer levosimendan on the performance of ischaemic myocardium in anaesthetised pigs. Cardiovasc Drugs Ther 16: 435-441
91. Tavernier B, Mebazaa A, Mateo P et al. (2001) Phosphorylation-dependent alteration in myofilament Ca2+ sensitivity but normal mitochondrial function in septic heart. Am J Respir Crit Care Med 163: 362-367
92. Than N, Shah N, White J et al. (1994) Effects of acidosis and hypoxia on the response of isolated ferret cardiac muscle to inotropic agents. Cardiovasc Res 28: 1209-1217
93. Toivonen L, Viitasalo M, Sundberg S et al. (2000) Electrophysiologic effects of a calcium sensitizer inotrope levosimendan administered intravenously in patients with normal cardiac function. J Cardiovasc Pharmacol 35: 664-669
94. Toit EF du, Muller CA, McCarthy J, Opie LH (1999) Levosimendan: effects of a calcium sensitizer on function and arrhythmias and cyclic nucleotide levels during ischemia/reperfusion in the Langendorff-perfused guinea pig heart. J Pharmacol Exp Ther 290(2): 505-514
95. Toit E du, Hofmann D, McCarthy J, Pineda C (2001) Effect of levosimendan on myocardial contractility, coronary and peripheral blood flow, and arrhythmias during coronary artery ligation and reperfusion in the in vivo pig model. Heart 86(1): 81-87
96. Toller W, Woelkart G, Stranz C, Brunner F (2005) Contractile action of levosimendan and epinephrine during acidosis. Eur J Pharmacol 507: 199-209
97. Trikas A, Antoniades C, Latsios G et al. (2006) Long-term effects of levosimendan infusion on inflammatory processes and sFas in patients with severe heart failure. Eur J Heart Fail [Epub ahead of print]
98. Tritapepe L, Santis V de, Vitale D et al. (2006) Preconditioning effects of levosimendan in coronary artery bypass grafting - A pilot study. Br J Anaesth 96(6): 694-700
99. Turani F, Aurisicchio P, D'Ercole P (2004) Hemodynamic and volumetric response to levosimendan in critical care patients. Crit Care 6: 84
100. Turanlahti M, Boldt T, Palkama T et al. (2004) Pharmacokinetics of levosimendan in pediatric patients evaluated for cardiac surgery. Pediatr Crit Care Med 5: 457-462
101. Ukkonen H, Saraste M, Akkila J et al. (2000) Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther 68(5): 522-531
102. Varadarajan SG, An JZ, Novalija E et al. (2001) Changes in [Na+]i, compartmental [Ca2+], and NADH with dysfunction after global ischemia in intact hearts. Am J Physiol Heart Circ Physiol 280: H280-293
103. Witt BJ de, Ibrahim IN, Bayer E et al. (2002) An analysis of responses to levosimendan in the pulmonary vascular bed of the cat. Anesth Analg 94(6): 1427-1433
104. Yokoshiki H, Sperelakis N (2003) Vasodilating mechanisms of levosimendan. Cardiovasc Drugs Ther 17: 111-113
105. Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N (1997) Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes. Eur J Pharmacol 333: 249-259
106. Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N (1997) The novel calcium sensitizer levosimendan activates the ATP-sensitive K+ channel in rat ventricular cells. J Pharmacol Exp Ther 283: 375-383
107. Zairis MN, Apostolatos C, Anastasiadis P (2004) The effect of a calcium sensitizer or an inotrope or none in chronic low output decompensated heart failure: results from the calcium sensitizer or an inotrope or none in low output heart failure study (CASINO). J Am Coll Cardiol 43: 206A-207A